natgillin/translations-raw huggingface dataset:
8 In active comparator controlled trials mean weight increase with pioglitazone given as monotherapy was 2-3 kg over one year. 
8 V kontroliranih preskušanjih z aktivno primerjavo je bilo povprečno povečanje telesne mase pri pioglitazonu, danemu kot monoterapija, 2-3 kg v enem letu.
The formation and presence of urinary calculi with subsequent irritation and hyperplasia was postulated as the mechanistic basis for the observed tumourigenic response in the male rat. 
Domnevali so, da je nastajanje in prisotnost kamnov v sečilih s poznejšim draženjem in hiperplazijo predstavljalo mehansko osnovo opaženega tumorogenega odgovora pri samcih podgan.
Neoplasms benign, malignant and unspecified (including cysts and polyps) bladder cancer uncommon uncommon 
Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi) rak sečnega mehurja občasni občasni
Mean levels of liver enzymes decreased with treatment with pioglitazone. 
Povprečne koncentracije jetrnih encimov so se z zdravljenjem s pioglitazonom nižale.
Taking into account the PRAC Assessment Report on the PSUR(s) for glimepiride / pioglitazone hydrochloride, metformin / pioglitazone, pioglitazone, the scientific conclusions of CHMP are as follows: 
Upoštevajoč poročilo Odbora za oceno tveganja na področju farmakovigilance (PRAC) o oceni rednih posodobljenih poročil o varnosti zdravila (PSUR) za glimepirid/pioglitazon hidroklorid, metformin/pioglitazon, pioglitazon je Odbor za zdravila za uporabo v humani medicini (CHMP) sprejel naslednje znanstvene zaključke:
When clinically appropriate, direct change from metformin monotherapy to Glubrava may be considered. 
Če je klinično sprejemljivo, se sme razmisliti o neposredni zamenjavi iz monoterapije z metforminom na zdravljenje z zdravilom Glubrava.
The observed excess risk of fractures for women on pioglitazone in this study is therefore 0.5 fractures per 100 patient years of use. 
Presežek tveganja za zlome pri ženskah, zdravljenih s pioglitazonom, opažen v tej študiji, je torej 0,5 zlomov na 100 bolnikov-let uporabe.
Gas trointe s tinal dis orders4 abdominal pain very common very common diarrhoea very common very common flatulence uncommon loss of appetite very common very common nausea very common very common vomiting very common very common 
Bolezni prebavil4 bolečine v trebuhu zelo pogosti zelo pogosti driska zelo pogosti zelo pogosti flatulenca občasni izguba apetita zelo pogosti zelo pogosti slabost zelo pogosti zelo pogosti bruhanje zelo pogosti zelo pogosti
If you need to have major surgery you must stop taking Glubrava during and for some time after the procedure. 
Če morate na večji kirurški poseg, morate v času posega in še nekaj časa po tem prenehati z jemanjem zdravila Glubrava.
Post marketing cases of peripheral oedema and cardiac failure have also been reported in patients with concomitant use of pioglitazone and nonsteroidal anti-inflammatory drugs, including selective COX-2 inhibitors. 
Po prihodu zdravila na trg so o primerih perifernega edema in srčnega popuščanja poročali tudi pri bolnikih, ki so se sočasno zdravili s pioglitazonom in z nesteroidnimi protivnetnimi zdravili, vključno s selektivnimi zaviralci COX-2.
if you are going to have a certain type of X-ray with an injectable dye, talk to your doctor as you must stop taking Glubrava for a certain period of time before and after the examination. 
- če imate predvideno rentgensko preiskavo, pri kateri vam bodo vbrizgali barvilo, se pogovorite s svojim zdravnikom, saj boste morali za določeno obdobje pred preiskavo in po njej prenehati z jemanjem zdravila Glubrava.
Your doctor will ask you to have blood tests periodically during treatment with Glubrava. 
Zdravnik vas bo v času zdravljenja z zdravilom Glubrava naročil na redne preiskave krvi.
9 In clinical trials with pioglitazone the incidence of elevations of ALT greater than three times the upper limit of normal was equal to placebo but less than that seen in metformin or sulphonylurea comparator groups. 
9 V kliničnih preskušanjih pioglitazona je bila incidenca povišanih vrednosti ALT, višjih kot trikratna zgornja meja normalnih vrednosti, enaka kot pri placebu, vendar nižja kot v primerjalnih skupinah metformina ali sulfonilsečnine.
Repeated dosing does not result in accumulation of the compound or metabolites. 
Večkratno odmerjanje ne povzroči kopičenja učinkovine ali presnovkov.
Polycystic ovarian syndrome 
Sindrom policističnih jajčnikov
by reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis in muscle, by modestly increasing insulin sensitivity, improving peripheral glucose uptake and utilisation by delaying intestinal glucose absorption. 
- zmanjšuje nastajanje glukoze v jetrih, tako da inhibira glukoneogenezo in glikogenolizo; - v mišicah zmerno poveča občutljivost za insulin, izboljša periferni vnos in izkoriščanje glukoze; - upočasni absorpcijo glukoze v črevesju.
Microcrystalline cellulose Povidone (K30) Croscarmellose sodium Magnesium stearate 
Jedro tablete mikrokristalna celuloza povidon (K30) natrijev karmelozat, premrežen magnezijev stearat
Since there is a potential for an increase in dose-related adverse events, a decrease in the dose of pioglitazone may be needed when gemfibrozil is concomitantly administered. 
Ker obstaja možnost povečanja od odmerka odvisnih neželenih dogodkov, bo morda ob sočasnem dajanju gemfibrozila treba znižati odmerek pioglitazona.
Pioglitazone was associated with significant weight gain. 
Pioglitazon je bil povezan s pomembnim povečanjem telesne mase.
Glubrava combines two antihyperglycaemic active substances with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes mellitus: pioglitazone, a member of the thiazolidinedione class and metformin hydrochloride, a member of the biguanide class. 
Zdravilo Glubrava je kombinacija dveh antihiperglikemičnih učinkovin s komplementarnim mehanizmom delovanja, namenjeno pa je izboljšanju urejenosti glikemije pri bolnikih s sladkorno boleznijo tipa 2: pioglitazona iz skupine tiazolidindionov in metforminijevega klorida iz skupine bigvanidov.
In most clinical trials, reduced total plasma triglycerides and free fatty acids, and increased HDL-cholesterol levels were observed as compared to placebo, with small, but not clinically significant increases in LDL-cholesterol levels. 
V večini kliničnih preskušanj so opažali znižane skupne plazemske koncentracije trigliceridov in prostih maščobnih kislin ter povišane ravni HDL holesterola v primerjavi s placebom, z majhnimi, vendar ne klinično pomembnimi povišanji ravni LDL holesterola.
However, the incidence of oedema, weight gain and heart failure were increased. 
Vendar je bila povečana incidenca edemov, pridobivanja telesne mase in srčnih odpovedi.
If you have any further questions on the use of this medicine ask your doctor or pharmacist. 
Če imate dodatna vprašanja o uporabi zdravila, se posvetujte z zdravnikom ali s farmacevtom.
If you have any further questions, ask your doctor or pharmacist. 
- Če imate dodatna vprašanja, se posvetujte z zdravnikom ali farmacevtom.
In patients on insulin with no pioglitazone the incidence of heart failure was 8.2% in those ≥ 65 years compared to 4.0% in patients less than 65 years. 
Pri bolnikih, ki so se zdravili samo z insulinom, brez pioglitazona, je odstotek srčnega popuščanja pri bolnikih, starih 65 let in starejših, znašal 8,2%, pri bolnikih, mlajših od 65 let, pa 4,0%.
There was a small reduction in mean haemoglobin (4% relative reduction) and haematocrit (4.1% relative reduction) during therapy with pioglitazone, consistent with haemodilution. 
Med zdravljenjem s pioglitazonom se je pojavljalo majhno znižanje povprečne vrednosti hemoglobina (4% relativno znižanje) in hematokrita (4,1% relativno znižanje), skladno s hemodilucijo.
Heart failure has been reported with marketing use of pioglitazone and more frequently when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure (see section 4.4). 
O srčnem popuščanju so poročali tudi pri tržni uporabi pioglitazona, in sicer pogosteje pri uporabi pioglitazona v kombinaciji z insulinom ali pri bolnikih z anamnezo srčnega popuščanja (glejte poglavje 4.4).
Proportional increases of the plasma concentration were observed for doses from 2-60 mg. 
Za odmerke od 2 do 60 mg so opažali sorazmerna povišanja plazemskih koncentracij.
This medicine will not affect your ability to drive or use machines but take care if you experience abnormal vision. 
Vpliv na sposobnost upravljanja vozil in strojev To zdravilo ne vpliva na sposobnost upravljanja vozil in strojev, vendar pa bodite pozorni v primeru pojava težav z vidom.
Intravascular administration of iodinated contrast agents (see section 4.4) Breast-feeding (see section 4.6) 
- šoku; - intravenski uporabi jodiranih kontrastnih sredstev (glejte poglavje 4.4); - dojenju (glejte poglavje 4.6).
In clinical trials of up to two years duration, pioglitazone reduced total plasma triglycerides and free fatty acids, and increased HDL-cholesterol levels, compared with placebo, metformin or gliclazide. 
V kliničnih preskušanjih, ki so trajala do dve leti, je pioglitazon znižal skupne plazemske trigliceride in proste maščobne kisline ter povišal ravni HDL holesterola v primerjavi s placebom, metforminom ali gliklazidom.
Liver enzymes should be checked prior to the initiation of therapy with Glubrava in all patients. 
Jetrne encime je treba pri vseh bolnikih kontrolirati pred uvedbo zdravljenja z zdravilom Glubrava.
In a 20-week study, as well as reducing fasting triglycerides, pioglitazone reduced postprandial hypertriglyceridaemia through an effect on both absorbed and hepatically synthesised triglycerides. 
V 20-tedenski študiji je pioglitazon znižal raven trigliceridov na tešče, pa tudi hipertrigliceridemijo po obroku prek učinkovanja na absorbirane in v jetrih sintetizirane trigliceride.
If you experience this symptom for the first time, talk to your doctor as soon as possible. 
Če imate ta simptom prvič, se čim prej posvetujte s svojim zdravnikom.
It is recommended, therefore, that patients treated with Glubrava undergo periodic monitoring of liver enzymes. 
Zato je priporočeno, da pri bolnikih, zdravljenih z zdravilom Glubrava, redno spremljate vrednosti jetrnih encimov.
Treatment with pioglitazone has been shown to reduce hepatic glucose output and to increase peripheral glucose disposal in the case of insulin resistance. 
Dokazali so, da zdravljenje s pioglitazonom znižuje izločanje glukoze iz jeter ter povišuje periferno porabo glukoze v primeru insulinske rezistence.
Post-marketing reports of new-onset or worsening diabetic macular oedema with decreased visual acuity have been reported with thiazolidinediones, including pioglitazone. 
Pri postmarketinškem spremljanju zdravila so poročali o nastopu ali poslabšanju diabetičnega makularnega edema s poslabšanjem ostrine vida pri tiazolidindionih, vključno s pioglitazonom.
Glubrava with alcohol 
Zdravilo Glubrava skupaj z alkoholom
Within each system organ class, adverse reactions are presented in order of decreasing incidence followed by decreasing seriousness. 
V razvrstitvah pogostnosti so neželeni učinki navedeni po padajoči resnosti.
Some medicinal products that can adversely affect renal function which may increase the risk of lactic acidosis, e.g. NSAIDS, including selective cyclo-oxygenase (COX) II inhibitors, ACE inhibitors, angiotensin II receptor antagonists and diuretics, especially loop diuretics. 
Kombinacije, pri katerih so potrebni previdnostni ukrepi Nekatera zdravila lahko škodljivo vplivajo na delovanje ledvic, kar lahko poveča tveganje za laktacidozo, npr. nesteroidna protivnetna zdravila, vključno s selektivnimi zaviralci ciklooksigenaze (COX) II, zaviralci ACE, antagonisti receptorjev angiotenzina II in diuretiki, zlasti diuretiki Henlejeve zanke.
Grounds for the variation to the terms of the Marketing Authorisation(s) 
Podlaga za spremembe pogojev dovoljenja (dovoljenj) za promet z zdravilom
Glubrava is indicated as second line treatment of type 2 diabetes mellitus adult patients, particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone. 
Zdravilo Glubrava je indicirano kot drugi izbor zdravljenja sladkorne bolezni tipa 2 pri odraslih, še posebno pri bolnikih s čezmerno telesno maso, pri katerih ni možno vzdrževati primerne koncentracije glukoze v krvi z največjim dovoljenim peroralnim odmerkom metformina samega.
Wed. 2 
Pet. 1 Pet. 2
Studies of pioglitazone in animals have shown reproductive toxicity (see section 5.3). 
Študije pioglitazona na živalih so pokazale vpliv na sposobnost razmnoževanja (glejte poglavje 5.3).
Glubrava is contraindicated during breast-feeding (see section 4.3). 
Zdravilo Glubrava je kontraindicirano med dojenjem (glejte poglavje 4.3).
How to take Glubrava 
Kako jemati zdravilo Glubrava
The improved glycaemic control is associated with a reduction in both fasting and postprandial plasma insulin concentrations. 
Izboljšan nadzor glikemije je povezan z znižanjem plazemskih koncentracij insulina tako med stradanjem kot po obrokih.
If necessary your doctor may tell you to take a different dose. 
Po potrebi lahko zdravnik odmerek spremeni.
Broken bones 
Zlomi kosti
An increased incidence in bone fractures in women was seen in a pooled analysis of adverse reactions of bone fracture from randomised, controlled, double blind clinical trials (see section 4.8). 
V skupni analizi neželenih učinkov zlomov kosti iz randomiziranih, kontroliranih, dvojno slepih kliničnih preskušanj so opazili povečano incidenco zlomov kosti pri ženskah (glejte poglavje 4.8).
Not known - inflammation of the liver (hepatitis) - liver does not work as well as it should (changes in liver enzymes) 
Neznana pogostnost - vnetje jeter (hepatitis) - motnje v delovanju jeter (sprememba vrednosti jetrnih encimov)
if you have cysts on your ovaries (polycystic ovary syndrome). 
- če imate ciste na jajčnikih (sindrom policističnih jajčnikov).
The risk of fractures should be considered in the long term care of patients treated with pioglitazone (see section 4.8). 
Pri dolgoročnem zdravljenju bolnikov s pioglitazonom je treba upoštevati tveganje za zlome (glejte poglavje 4.8).
In vitro studies have shown no evidence that pioglitazone inhibits any subtype of cytochrome P450. 
Študije in vitro niso dale dokazov, da pioglitazon inhibira katerikoli podtip citokroma P450.
56 tablets 
56 tablet
If jaundice is observed, the medicinal product should be discontinued. 
Če se pojavi zlatenica, je treba zdravilo ukiniti.
Patients with hepatic impairment 
Bolniki z jetrno okvaro
Glubrava must be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable, see sections 4.2 and 4.4. 
Glubrava je treba pred slikanjem ali v času slikanja ukiniti in se ga sme ponovno uvesti najmanj 48 ur pozneje, če je bilo delovanje ledvic ponovno ovrednoteno in ocenjeno kot stabilno, glejte poglavji 4.2 in 4.4.
This can lead to a risk of hypoglycaemia (low blood sugar): - gemfibrozil (to lower high cholesterol level) - angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists (to treat high blood pressure) - cimetidine (to reduce stomach acid) 
To lahko povzroči tveganje za hipoglikemijo (nizka raven sladkorja v krvi): - gemfibrozil (za zniževanje visoke ravni holesterola) - zaviralci angiotenzinske konvertaze (zaviralci ACE) in antagonisti receptorjev angiotenzina II
He patobiliary dis orde rs hepatitis5 
Bolezni jeter, žolčnika in žolčevodov hepatitis5
There may be an increased possibility of becoming pregnant because you may ovulate again when you take Glubrava. 
Obstaja povečana možnost zanositve, saj se pri jemanju zdravila Glubrava ovulacija lahko povrne.
What Glubrava contains The active substances are pioglitazone and metformin hydrochloride. 
Kaj vsebuje zdravilo Glubrava - Zdravilni učinkovini sta pioglitazon in metforminijev klorid.
Concomitant administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) or with rifampicin (an inducer of cytochrome P450 2C8) is reported to increase or decrease, respectively, the plasma concentration of pioglitazone (see section 4.5). 
Poročali so, da sočasno dajanje pioglitazona z gemfibrozilom (zaviralcem citokroma P450 2C8) ali z rifampicinom (induktorjem citokroma P450 2C8) poviša oziroma zniža plazemsko koncentracijo pioglitazona (glejte poglavje 4.5).
In toxicology studies, plasma volume expansion with haemodilution, anaemia, and reversible eccentric cardiac hypertrophy was consistently apparent after repeated dosing of mice, rats, dogs, and monkeys. 
V študijah toksičnosti so se po večkratnem odmerjanju mišim, podganam, psom in opicam stalno pojavljali povečanje volumna plazme s hemodilucijo, anemija in reverzibilna ekscentrična hipertrofija srca.
After oral administration, metformin absorption is saturable and incomplete. 
Po peroralnem dajanju je absorpcija metformina zasičena in ni popolna.
Similar changes were seen in metformin (haemoglobin 3-4% and haematocrit 3.6-4.1% relative reductions) treated patients in comparative controlled trials with pioglitazone. 
Podobne spremembe so opažali v primerjalnih kontroliranih preskušanjih s pioglitazonom pri bolnikih, zdravljenih z metforminom (hemoglobin 3-4% in hematokrit 3,6-4,1% relativna znižanja).
Glubrava is not recommended in women of childbearing potential not using contraception. 
Zdravila Glubrava ne uporabljajte pri ženskah v rodni dobi, ki ne uporabljajo učinkovite kontracepcije.
After an oral dose of metformin, tmax is reached in 2.5 h. Absolute bioavailability of a 500 mg metformin tablet is approximately 50-60% in healthy subjects. 
Pri zdravih posameznikih je absolutna biološka uporabnost 500 mg tablete metformina približno 50 do 60%.
Bladder cancer 
Rak sečnega mehurja
A higher rate of fractures was observed in women taking pioglitazone (2.6%) versus comparator (1.7%). 
Opazili so višjo stopnjo zlomov pri ženskah, ki so jemale pioglitazon (2,6%) v primerjavi s primerjalnim zdravilom (1,7%).
Glubrava should be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable, see sections 4.2 and 4.5. 
Glubrava je treba pred slikanjem ali v času slikanja ukiniti in se ga sme ponovno uvesti najmanj 48 ur pozneje, če je bilo delovanje ledvic ponovno ovrednoteno in ocenjeno kot stabilno, glejte poglavji 4.2 in 4.5.
FOR CALENDARISED PACKS: Mon. 1 
OKRAJŠAVE ZA DNI V TEDNU ZA KOLEDARSKA PAKIRANJA: Pon.
Blurred vision due to swelling (or fluid) at the back of the eye (macular oedema) has also been reported in patients taking Glubrava (frequency cannot be estimated from the available data). 
Pri bolnikih, ki so jemali zdravilo Glubrava, so poročali o motnjah vida zaradi otekanja (ali tekočine) v zadnjem delu očesa (makularni edem) (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti).
A higher number of bone fractures was seen in patients, particularly women taking pioglitazone. 
Pri bolnikih, ki so se zdravili s pioglitazonom, še posebej ženskah, so poročali o večjem številu zlomov kosti.
There have been rare reports of elevated liver enzymes and hepatocellular dysfunction during post-marketing experience with pioglitazone (see section 4.8). 
V postmarketinških izkušnjah s pioglitazonom so poročali o redkih primerih povišanih jetrnih encimov in hepatocelularne disfunkcije (glejte poglavje 4.8).
98 tablets 
98 tablet
No increase in fracture rates was observed in men treated with pioglitazone (1.3%) versus comparator (1.5%). 
Pri moških, zdravljenih s pioglitazonom, niso opazili povečane stopnje zlomov (1,3%) v primerjavi s primerjalnim zdravilom (1,5%).
Factors that may increase the risk of lactic acidosis (see section 4.4) should be reviewed before considering initiation of metformin in patients with GFR < 60 mL/min. 
Pri bolnikih z GFR < 60 ml/min je treba pred uvedbo metformina pregledati dejavnike, ki lahko povečajo tveganje za laktacidozo (glejte poglavje 4.4).
Glubrava 15 mg/850 mg 
PODATKI V BRAILLOVI PISAVI Glubrava 15 mg/850 mg
If a pregnancy occurs, treatment with Glubrava should be discontinued. 
Če pride do nosečnosti, je potrebno zdravljenje z zdravilom Glubrava prekiniti.
The recommended dose of Glubrava is 30 mg/day pioglitazone plus 1,700 mg/day of metformin hydrochloride (this dose is achievable with one tablet of Glubrava 15 mg/850 mg, taken twice a day). 
Odrasli z normalnim delovanjem ledvic (GFR ≥ 90 ml/min) Priporočeni odmerek zdravila Glubrava je 30 mg/dan pioglitazona in 1.700 mg/dan metforminijevega klorida (dan v obliki ene tablete zdravila Glubrava 15 mg/850 mg dvakrat na dan).
Maximum daily dose is 45 mg 
Brez prilagajanja odmerka Največji dnevni odmerek je 45 mg.
Glubrava should not be used during pregnancy. 
Zdravila Glubrava se ne sme dajati ženskam v času nosečnosti.
There have been post-marketing cases of cardiac failure reported when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure. 
V času trženja zdravila so poročali o primerih srčnega popuščanja, ko so pioglitazon uporabljali v kombinaciji z insulinom ali pri bolnikih s srčnim popuščanjem v anamnezi.
28 tablets 
28 tablet
No increase in fracture rates was observed in men treated with pioglitazone (1.7%) versus comparator (2.1%). 
Pri moških, zdravljenih s pioglitazonom, niso opazili povečane stopnje zlomov (1,7%) v primerjavi s primerjalnim zdravilom (2,1%).
Dose titration with pioglitazone (added to the optimal dose of metformin) should be considered before the patient is switched to Glubrava. 
Preden se bolnika prevede na zdravljenje z zdravilom Glubrava, je treba najprej prilagoditi odmerek pioglitazona (dodajanje k optimalnemu odmerku metformina).
90 tablets 
90 tablet
The following medicines may decrease the blood sugar lowering effect of Glubrava. 
Naslednja zdravila lahko zmanjšajo učinek zdravila Glubrava na znižanje ravni sladkorja v krvi.
Non-clinical data for metformin reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction. 
Predklinični podatki o metforminu na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih odmerkih, genotoksičnosti, kancerogenega potenciala, vpliva na sposobnost razmnoževanja ne kažejo posebnega tveganja za človeka.
Co-administration of pioglitazone with rifampicin (an inducer of cytochrome P450 2C8) is reported to result in a 54% decrease in AUC of pioglitazone. 
Poročali so, da sočasno dajanje pioglitazona z rifampicinom (induktorjem citokroma P450 2C8) povzroči 54% zmanjšanje AUC pioglitazona.
30 tablets 
30 tablet
Glubrava 15 mg/850 mg film-coated tablets pioglitazone/metformin hydrochloride 
Glubrava 15 mg/850 mg filmsko obložene tablete pioglitazon/metforminijev klorid
Common weight gain headache respiratory infection abnormal vision joint pain impotence blood in urine reduction in blood count (anaemia) numbness taste disturbance 
Pogosti - povečanje telesne mase - glavobol - okužba dihal - motnje vida - bolečine v sklepih - impotenca - kri v urinu - zmanjšanje števila krvnih celic (anemija) - odrevenelost - motnje čuta za okušanje
45-59 Maximum daily dose is 2,000 mg The starting dose is at most half of the maximum dose. 
45 do 59 Največji dnevni odmerek je 2.000 mg.
The following medicines can increase the blood sugar lowering effect of Glubrava. 
Naslednja zdravila lahko okrepijo učinek zdravila Glubrava na znižanje ravni sladkorja v krvi.
Therapy with Glubrava should not be initiated in patients with increased baseline liver enzyme levels (ALT > 2.5 x upper limit of normal) or with any other evidence of liver disease. 
Pri bolnikih s povišanimi izhodiščnimi vrednostmi jetrnih encimov (ALT > 2,5-kratna zgornja meja normalnih vrednosti) ali s kakršnimi koli drugimi znaki jetrne bolezni, zdravljenja z zdravilom Glubrava ne smemo začeti.